MRI FOR PRE-DEMENTIA TRIALS

2015 ◽  
pp. 1-3
Author(s):  
G.B. Frisoni ◽  
M. Boccardi
Keyword(s):  
Magnetic Resonance Imaging ◽  
Clinical Trials ◽  
Magnetic Resonance ◽  
Early Stage ◽  
Good Reproducibility ◽  
Resonance Imaging ◽  
Clinical Progression ◽  
Structural Magnetic Resonance Imaging ◽  
High Measurement ◽  
Magnetic Resonance Imaging Mri

Structural magnetic resonance imaging (MRI) provides valid markers of whole brain and regional areas of atrophy in Alzheimer’s disease (AD), which are sensitive to change and correlate with clinical progression. Recent efforts to develop standardized and harmonized protocols for MRI indicate high measurement stability and good reproducibility, supporting the use of these measures in clinical trials. Newer MRI measures of microstructural and connectivity changes are also showing promise as early stage biomarkers of neurodegeneration and potentially as measures of treatment effects. Further work is needed to validate these markers for use in clinical trials.

scholarly journals Using magnetic resonance imaging in animal models to guide drug development in multiple sclerosis

2013 ◽  
Vol 20 (1) ◽  
pp. 3-11 ◽  
Author(s):  
Nabeela Nathoo ◽  
V Wee Yong ◽  
Jeff F Dunn
Keyword(s):  
Magnetic Resonance Imaging ◽  
Multiple Sclerosis ◽  
Clinical Trials ◽  
Magnetic Resonance ◽  
Animal Models ◽  
Mr Imaging ◽  
Preclinical Studies ◽  
Resonance Imaging ◽  
Magnetic Resonance Imaging Mri ◽  
Potential Therapeutics

Major advances are taking place in the development of therapeutics for multiple sclerosis (MS), with a move past traditional immunomodulatory/immunosuppressive therapies toward medications aimed at promoting remyelination or neuroprotection. With an increase in diversity of MS therapies comes the need to assess the effectiveness of such therapies. Magnetic resonance imaging (MRI) is one of the main tools used to evaluate the effectiveness of MS therapeutics in clinical trials. As all new therapeutics for MS are tested in animal models first, it is logical that MRI be incorporated into preclinical studies assessing therapeutics. Here, we review key papers showing how MR imaging has been combined with a range of animal models to evaluate potential therapeutics for MS. We also advise on how to maximize the potential for incorporating MRI into preclinical studies evaluating possible therapeutics for MS, which should improve the likelihood of discovering new medications for the condition.

Magnetic Resonance Imaging of Axial and Peripheral Disease in Psoriatic Arthritis: A Report From the 2020 GRAPPA Annual Meeting

2021 ◽  
pp. jrheum.201676
Author(s):  
Walter P. Maksymowych ◽  
Mikkel Østergaard
Keyword(s):  
Magnetic Resonance Imaging ◽  
Clinical Trials ◽  
Psoriatic Arthritis ◽  
Magnetic Resonance ◽  
Imaging Modality ◽  
Scoring Systems ◽  
Resonance Imaging ◽  
Structural Abnormalities ◽  
The Status ◽  
Magnetic Resonance Imaging Mri

Psoriatic arthritis (PsA) presents with diverse features of musculoskeletal inflammation that affect both axial and peripheral joints as well as entheses, tenosynovium, and bursae. Magnetic resonance imaging (MRI) is the imaging modality that is uniquely capable of identifying pathology in all these structures. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Magnetic Resonance Imaging Working Group has increasingly explored diverse MRI methodologies for the purposes of quantifying inflammatory and structural abnormalities in clinical trials and research. The 2020 GRAPPA virtual workshop presented an opportunity to review progress in the field, summarize the status of MRI scoring systems developed for PsA, and review representative patient cases.

Selecting Magnetic Resonance Imaging (MRI) Outcome Measures for Juvenile Idiopathic Arthritis (JIA) Clinical Trials: First Report of the MRI in JIA Special Interest Group

2013 ◽  
Vol 41 (2) ◽  
pp. 354-358 ◽  
Author(s):  
Robert Hemke ◽  
Andrea S. Doria ◽  
Nikolay Tzaribachev ◽  
Mario Maas ◽  
Désirée M.F.M van der Heijde ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Magnetic Resonance Imaging ◽  
Clinical Trials ◽  
Juvenile Idiopathic Arthritis ◽  
Magnetic Resonance ◽  
Childhood And Adolescence ◽  
Resonance Imaging ◽  
Scoring Method ◽  
Magnetic Resonance Imaging Mri ◽  
Clinical Research Trials

Recent advances in magnetic resonance imaging (MRI) techniques have substantially improved the evaluation of joint pathologies in juvenile idiopathic arthritis (JIA). Because of the current availability of highly effective antirheumatic therapies and the unique and useful features of MRI, there is a growing need for an accurate and reproducible MRI assessment scoring system for JIA, such as the rheumatoid arthritis MRI Scoring (RAMRIS) for patients with rheumatoid arthritis (RA). To effectively evaluate the efficacy of treatment in clinical research trials, we need to develop and validate scoring methods to accurately measure joint outcomes, standardize imaging protocols for data acquisition and interpretation, and create imaging atlases to differentiate physiologic and pathologic joint findings in childhood and adolescence. Such a standardized, validated, JIA-MRI scoring method could be used as an outcome measure in clinical trials.

Sign in / Sign up

Export Citation Format

Share Document